Taltz revenue trends
In 1H17, Eli Lilly’s (LLY) Taltz reported revenues of ~$235.3 million, compared with $19.3 million in 1H16. In 2Q17, Taltz generated revenues of around $138.7 million, compared with $19.3 million in 2Q16. In 2Q17, Taltz witnessed 44% growth QoQ (quarter-over-quarter).
In 2Q17, in US markets, and outside the US, Taltz generated revenues of around $124.4 million and $14.3 million, respectively. In 1H17, in US markets, while outside US markets, Taltz generated revenues of ~$212.3 million and $23.1 million, respectively.
Taltz (ixekizumab) is used for the treatment of adult individuals with moderate-to-severe plaque psoriasis who are subjects for systemic therapy or phototherapy.
In June 2017, Eli Lilly announced that results from the extended period of the Spirit-P1 trial showed that the majority of patients with active PsA (psoriatic arthritis), when treated with Taltz, showed no progress or minimal progress of radiographic structural joint damage over 52 weeks of therapy.
In June 2017, Eli Lilly presented the results from the Spirit-P2 trial. In the trial, PsA patients who did not respond adequately to one or two TNF (tumor necrosis factor) inhibitors (or were intolerant to TNF inhibitors), when treated with Taltz, demonstrated substantial improvement in signs and symptoms of disease in the 24th week, compared with patients on placebo therapy.
The primary endpoint of the Spirit-P2 study was to determine the percentage of patients achieving minimum 20% decrease in the composite measure of disease activity, according to the American College of Rheumatology. In the Spirit-P2 trial, 53% and 48% of patients on Taltz every four weeks and Taltz every two weeks, respectively, achieved ACR20, compared with 19% of the patients on placebo therapy.
In the same trial, 35% and 33% of patients on Taltz every four weeks and Taltz every two weeks, respectively, achieved ACR50, compared with 5% of patients on placebo treatment. The trial also demonstrated that 22% and 12% patients on Taltz every four weeks and Taltz every two weeks, respectively, achieved ACR70, while no patients on the placebo therapy could achieve ACR70.
Notably, Eli Lilly has submitted a sBLA (supplemental Biologics License Application) to the FDA (US Food and Drug Administration) for Taltz as a treatment for adult patients with active PsA. In Japan, Taltz has already received approval for adult individuals with active PsA.
Eli Lilly’s Taltz competes with Novartis’ (NVS) Cosentyx, AbbVie’s (ABBV) Humira, Johnson & Johnson’s (JNJ) Stelara, and Valeant Pharmaceuticals’ Siliq. The Vanguard Health Care ETF (VHT) has ~2.31% of its total portfolio holdings in LLY.